Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172821 | 1.00 | APLNR (0.66) | APLNRCA2CA12CA1CA7 | |
| Ammonia Solution, Strong SCHEMBL266597 | 0.98 | APLNR (0.63) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL24075695 | 0.86 | APLNR (0.50) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL13634446 | 0.86 | APLNR (0.50) | APLNRMAPTHSD17B10KMT2ATAAR1 | |
| SCHEMBL24064871 | 0.86 | APLNR (0.50) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL1046460 | 0.85 | APLNR (0.63) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL145084 | 0.84 | APLNR (0.68) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL6123805 | 0.83 | APLNR (0.61) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL17450548 | 0.83 | APLNR (0.47) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL11835484 | 0.83 | APLNR (0.47) | APLNRCA2CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029429-A1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | OGEDA SA (BE) | 2017-02-02 | — | — | US | claimed |
| EP-2763992-B9 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, AND METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS | EUROSCREEN SA (BE) | 2016-08-24 | — | — | EP | claimed |
| EP-3029042-A1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | Euroscreen S.A. (BE) | 2016-06-08 | — | — | EP | claimed |
| EP-2763992-B1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, AND METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS | EUROSCREEN SA (BE) | 2016-04-06 | — | — | EP | claimed |
| US-20140275097-A1 | NOVEL CHIRAL N-ACYL-5,6,7(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | OGEDA SA (BE) | 2014-09-18 | — | — | US | claimed |
| EP-2763992-A1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | Euroscreen S.A. (BE) | 2014-08-13 | — | — | EP | claimed |
| WO-2013050424-A1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | EUROSCREEN S.A. (BE) | 2013-04-11 | — | — | WO | claimed |
| US-7749985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2010-07-06 | — | — | US | claimed |
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-7585996-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-08 | — | — | US | claimed |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2008-06-19 | — | — | US | claimed |
| WO-2008033572-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-0767174-A1 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1997-04-09 | — | — | EP | claimed |
| US-5376684-A | Aminobutyric acid antagonist; antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1994-12-27 | — | — | US | claimed |
| EP-0543780-A2 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1993-05-26 | — | — | EP | claimed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-0543780-A2 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1993-05-26 | — | — | EP | disclosed |
| EP-0543780-A2 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1993-05-26 | — | — | EP | disclosed |
| US-4229479-A | BACTERIOSTATS, FUNGISTATS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, NAPEPLD, AASDHPPT | APLNR 259/4885CA2 235/4885CA12 631/4885 |
| US-20170029429-A1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | ACKR3, GPR3, TAC3 | APLNR 86/4885CA2 2875/4885CA12 3464/4885 |
| US-20140275097-A1 | NOVEL CHIRAL N-ACYL-5,6,7(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | ACKR3, GPR3, TAC3 | APLNR 85/4885CA2 2830/4885CA12 3310/4885 |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, NAPEPLD, AASDHPPT | APLNR 259/4885CA2 235/4885CA12 631/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | APLNR 3390/4885CA2 199/4885CA12 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.